BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 1998

View Archived Issues

Dimethaid Research: nine-month highlights

Read More

Roche describes new agents for neurodegenerative disorders

Read More

ABT-431, an improved therapeutic option for PD

Read More

MOR-14 exhibits protective potential against ischemic damage

Read More

Company Profile: MTR Technologies

Read More

AmBisome and DaunoXome receive additional approvals

Read More

Fujisawa outlicenses veterinary anthelmintic agent to Bayer

Read More

Astra obtains rights from Takeda to develop TxA2 antagonist

Read More

Another series of substance P antagonists discovered at Pfizer

Read More

Oral and parenteral formulations of levofloxacin now available in U.K.

Read More

KW-2170: in vitro and in vivo antitumor activity of a new pyrazoloacridone

Read More

Allelix: Q2 FY 1998 highlights

Read More

Fraxiparine now listed on Canadian health plan formularies

Read More

Cheung seeks FDA approval to begin testing of BPH treatment system

Read More

Gastric prokinetic effects and safety of EM-574 in healthy subjects

Read More

New PDE IV inhibitors for asthma reported by Celltech

Read More

Patient dosing begins in trial of Allelix's selective serotonin agonist

Read More

Meridian signs supply agreement with HGSI for cancer therapies

Read More

Cancer drug discovery alliance formed

Read More

CETP inhibitors for lipoprotein disorders discovered at Bayer

Read More

Gilead prepares orally active prodrugs of PMPA

Read More

Pipeline update from Yuhan

Read More

Nasally delivered influenza vaccine enters phase I

Read More

Low-dose oral interferon alfa: a patient-friendly treatment for chronic diseases on the horizon

Read More

hu1124 shows clinical activity in phase I for psoriasis

Read More

Fullerenol-1: a fullerene derivative for the treatment of atherosclerosis

Read More

Naturally occurring inhibitors of ICAM-1-mediated cell adhesion discovered by Taisho

Read More

Dopaminergic compound CI-1007 evaluated in schizophrenic patients

Read More

Intrathecal SNX-111 for acute postoperative pain

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing